Scientific Results

Since the start of the Domore! project, the ambitious expectations have been met. We are on the verge of completing the transferal from today’s complex human decision-making to an AI-based system ready for clinical use by the end of 2021.

The DoMore! project has resulted in several high impact academic publications. The results are disseminated through multimedia such as news articles, illustrative videos, and podcasts. Major developments and results are posted here.

The Domore! project - a presentation of the five-year long Lighthouse project financed by the Norwegian Research Council

After five years of collaboration with users, public partners and commercial players the Domore! project concluded in 2021. The final report describes results emerging from the project as well as challenges ahead.

PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer

Published in Cancers, Basel,
August 2021

New investors for DoMore! Diagnostics

Norselab and Grotmol invest 15 mill nok in DoMore! Diagnostics, enabling further development and better treatment for cancer patients.

Patent application submitted

The CDoMore-v1-CRC is a marker aiding doctors and pathologists in giving a more precise prognosis for patients with colorectal cancer.

Designing deep learning studies in cancer diagnostics

If artificial intelligence-based technology for cancer diagnostics exists, why is it still not in use? How can new knowledge in deep learning and artificial intelligence in diagnostics benefit cancer patients in the fastest and safest way? Read our discussion of reasons behind the moderate progress and description for remedies designed to facilitate the transition from research to clinical use.

Artificial Intelligence in cancer treatment

Listen to Håvard E. Danielsen explaining Domore! and the use of artificial intelligence in cancer prognostication and diagnostics in thsi podcast from NORA (Norwegian Artificial Intelligence Research Consortium).

AI transformation of medical practices can go faster with better design of deep learning studies

- according to a Perspective from ICGI researchers.

DoMore! Diagnostics

The DoMore!-project has reached the chapter on commercialization. Inven2's project manager Elin Melby says she has great faith in the company's potential.

Deep learning for prediction of colorectal cancer outcome: a discovery and validation study

Published in the Lancet,
1st February 2020

Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer

Published in the International Journal of Cancer,
December 2019

Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer

Published in Modern Pathology,
December 2019

Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers

Published in the Journal of the National Cancer Institute, 18.04.2018

The Lancet article presented at Oslo Life Science 2020

10th February 2020

The DoMore! Mid-Term Report

At the end of 2018, we reached the mid-way point of the 5-year long project, and this report reflects the challenges and results so far.

Providing prognostication using AI-based markers as a diagnostic service

Chromatin organisation and cancer prognosis: a pan-cancer study

Published in the Lancet Oncology, 02.02.2018

Clinical utility of chromatin analysis

Editorial in Oncotarget, 21.08.2018

How AI changes the prognostication of cancer

Kari Andresen, head of the Unit for Dissemination and Visualisation, has written an article about the DoMore! project.
7. June 2019

DoMore! presented at the launch of the National Health and Hospital Plan for 2020 and onward.

31. October 2019

DoMore! and AI presented at the Norwegian Oncology Forum 2019

Prognostic markers for colorectal cancer; estimating ploidy and stroma

Published in the Annals of Oncology, 01.02.2018

Tumour heterogeneity poses a significant challenge to cancer biomarker research

Published in the British Journal of Cancer, 25.07.2017